Miwon Chemicals Past Earnings Performance
Past criteria checks 5/6
Miwon Chemicals has been growing earnings at an average annual rate of 14.4%, while the Chemicals industry saw earnings growing at 6.9% annually. Revenues have been growing at an average rate of 11.7% per year. Miwon Chemicals's return on equity is 16.5%, and it has net margins of 10.6%.
Key information
14.4%
Earnings growth rate
14.2%
EPS growth rate
Chemicals Industry Growth | 13.9% |
Revenue growth rate | 11.7% |
Return on equity | 16.5% |
Net Margin | 10.6% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Returns On Capital At Miwon Chemicals (KRX:134380) Have Hit The Brakes
Mar 25Should Miwon Chemicals (KRX:134380) Be Disappointed With Their 38% Profit?
Feb 24Do Fundamentals Have Any Role To Play In Driving Miwon Chemicals Co., Ltd.'s (KRX:134380) Stock Up Recently?
Feb 09Is Miwon Chemicals Co., Ltd.'s (KRX:134380) Shareholder Ownership Skewed Towards Insiders?
Jan 25Here's Why I Think Miwon Chemicals (KRX:134380) Is An Interesting Stock
Jan 10We're Watching These Trends At Miwon Chemicals (KRX:134380)
Dec 25Does Miwon Chemicals (KRX:134380) Have A Healthy Balance Sheet?
Dec 10Can You Imagine How Miwon Chemicals' (KRX:134380) Shareholders Feel About The 39% Share Price Increase?
Nov 25Revenue & Expenses Breakdown
How Miwon Chemicals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 243,018 | 25,828 | 17,306 | 950 |
31 Mar 24 | 238,334 | 24,157 | 16,646 | 892 |
31 Dec 23 | 232,616 | 21,814 | 16,180 | 884 |
30 Sep 23 | 226,286 | 18,237 | 15,496 | 853 |
30 Jun 23 | 235,399 | 19,522 | 15,620 | 928 |
31 Mar 23 | 234,381 | 17,537 | 15,614 | 962 |
31 Dec 22 | 235,166 | 16,261 | 15,445 | 980 |
30 Sep 22 | 235,771 | 18,149 | 15,262 | 945 |
30 Jun 22 | 220,583 | 13,793 | 14,624 | 981 |
31 Mar 22 | 210,722 | 12,349 | 14,182 | 916 |
31 Dec 21 | 197,470 | 11,350 | 13,807 | 834 |
30 Sep 21 | 181,484 | 10,241 | 13,016 | 875 |
30 Jun 21 | 173,257 | 11,090 | 12,825 | 762 |
31 Mar 21 | 163,664 | 12,552 | 12,748 | 718 |
31 Dec 20 | 160,234 | 13,777 | 12,501 | 678 |
30 Sep 20 | 161,492 | 15,140 | 12,493 | 486 |
30 Jun 20 | 160,882 | 15,975 | 12,120 | 376 |
31 Mar 20 | 160,807 | 15,018 | 11,568 | 302 |
31 Dec 19 | 154,724 | 13,507 | 11,354 | 255 |
30 Sep 19 | 145,281 | 12,082 | 10,569 | 212 |
30 Jun 19 | 139,018 | 9,178 | 10,213 | 184 |
31 Mar 19 | 142,325 | 7,711 | 10,309 | 189 |
31 Dec 18 | 146,485 | 7,370 | 10,120 | 213 |
30 Sep 18 | 151,589 | 9,998 | 11,477 | 325 |
30 Jun 18 | 157,555 | 11,771 | 13,098 | 395 |
31 Mar 18 | 152,684 | 12,722 | 13,850 | 427 |
31 Dec 17 | 151,063 | 13,579 | 14,484 | 450 |
30 Sep 17 | 149,429 | 11,441 | 14,348 | 471 |
30 Jun 17 | 144,009 | 11,832 | 13,410 | 463 |
31 Mar 17 | 141,413 | 12,896 | 12,916 | 470 |
31 Dec 16 | 139,901 | 13,735 | 12,696 | 451 |
30 Sep 16 | 140,389 | 13,728 | 12,426 | 413 |
30 Jun 16 | 142,887 | 13,588 | 12,322 | 403 |
31 Mar 16 | 143,779 | 12,453 | 12,350 | 357 |
31 Dec 15 | 145,730 | 11,764 | 12,507 | 340 |
30 Sep 15 | 148,864 | 11,513 | 12,545 | 332 |
30 Jun 15 | 148,478 | 10,025 | 12,499 | 334 |
31 Mar 15 | 152,172 | 9,310 | 12,562 | 363 |
31 Dec 14 | 151,807 | 8,927 | 12,191 | 387 |
30 Sep 14 | 152,092 | 9,737 | 11,945 | 380 |
30 Jun 14 | 151,283 | 10,095 | 11,920 | 389 |
31 Mar 14 | 146,993 | 10,480 | 11,646 | 410 |
31 Dec 13 | 144,247 | 10,490 | 11,497 | 401 |
Quality Earnings: A134380 has high quality earnings.
Growing Profit Margin: A134380's current net profit margins (10.6%) are higher than last year (8.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A134380's earnings have grown by 14.4% per year over the past 5 years.
Accelerating Growth: A134380's earnings growth over the past year (32.3%) exceeds its 5-year average (14.4% per year).
Earnings vs Industry: A134380 earnings growth over the past year (32.3%) exceeded the Chemicals industry 2.5%.
Return on Equity
High ROE: A134380's Return on Equity (16.5%) is considered low.